Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04837547
Status:
RECRUITING
Last Update Posted:
2024-04-11
First Post:
2021-04-06
Brief Title:
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
Sponsor:
University of Florida
Organization:
University of Florida
Study Overview
Official Title:
PEACH TRIAL- Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma DIPG
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PEACH
Brief Summary:
A Phase I open-label multicenter study to evaluate the safety feasibility and maximum tolerated dose MTD of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy Total tumor mRNA-pulsed autologous Dendritic Cells DCs TTRNA-DCs Tumor-specific ex vivo expanded autologous lymphocyte transfer TTRNA-xALT and Autologous G-CSF mobilized Hematopoietic Stem Cells HSCs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None